Адаптована клінічна настанова, заснована на доказах (стр. 45 )

bowel diseases: prevalence, immunohistochemical characteristics and diagnostic role. Am J Gastroenterol 2000;95: 705–11.

142. Levine D, Reid B. Endoscopic biopsy technique for acquiring larger mucosal samples. Gastrointest Endosc 1991;37:332–7.

143. Rozen P, Baratz M, Fefer F, Gilat T. Low incidence of significant dysplasia in a successful endoscopic surveillance program of patients with ulcerative colitis. Gastroenterology 1995;108: 1361–70.

144. Riddell RH, Goldman H, Ransohoff DF, Appelman HD, Fenoglio CM, Haggitt RC, et al. Dysplasia in inflammatory bowel disease: Standardized classification with provisional clinical applications. Hum Pathol 1983;14:931–68. 145. Farmer M, Petras RE, Hunt LE, Janosky JE, Galandiuk S. The

importance of diagnostic accuracy in colonic inflammatory bowel disease. Am J Gastroenterol 2000;95:3184–8.

146. Sheehan AL, Warren BF, Gear MW, Shepherd NA. Fat-wrapping in Crohn's disease: pathological basis and relevance to surgical practice. Br J Surg 1992;79:955–8.

147. Borley NR, Mortensen NJ, Jewell DP, Warren BF. The relationship between inflammatory and serosal connective tissue change in ileal Crohn's disease: evidence for a possible causative link. J Pathol 2000;190:196–202.

148. Wright R, Truelove SC. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am J Dig Dis 1964;11:847–57.

149. Odze R, Antonioli D, Peppercorn M, Goldman H. Effect of topical 5-amino-salicylic acid (5-ASA) therapy on rectal mucosal biopsy morphology in chronic ulcerative colitis. Am J Surg Pathol 1993;17:869–75.

150. Riley SA, Mani V, Goodman MJ, Dutt S, Herd ME. Microscopic activity in ulcerative colitis: what does it mean? Gut 1991;32: 174–8.

151. Bitton A, Peppercorn MA, Antonioli DA, Niles JL, Sha S, Bousvaros A, et al. Clinical, biological and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology2001;120:13–20.

152. Korelitz BJ, Sommers SC. Response to drug therapy in Crohn's disease: Evaluation by rectal biopsy and mucosal cell counts. J Clin Gastroenterol 1984;6:123–7.

153. D'HaensG, Geboes K, Ponette E, Pennincks F, Rutgeerts P. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 1997;112:1475–81.

154. D'Haens G, Van Deventer S, Van Hogezand R, Chalmers D, Kothe C, Baert F, et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's diseas: a European multicenter trial. Gastroenterology 1999;116:1029–34.

155. Nicholls S, Domizio P, Williams CB, Dawnay A, Braegger CP, MacDonald TT, et al. Cyclosporin as initial treatment for Crohn's disease. Arch Dis Child 1994;71:243–7.

156. Beattie RM, Schiffrin EJ, Donnet-Hughes A, Huggett AC, Domizio P, MacDonald TT, et al. Polymeric nutrition as the primary therapy in children with small bowel Crohn's disease. Aliment Pharmacol Ther 1994;8:609–15.

157. Breese EJ, Michie CA, Nicholls SW, Murch SH, Williams CB, Domizio P, et al. Tumor necrosis factor alpha producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 1994;106:1455–66.

158. Fell JME, Paintin M, Arnaud-Battandier F, Beattie RM, Hollis A, Kitching P, et al. Mucosal healing and a fall in mucosal proinflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment Pharmacol Ther 2000;14:281–9.

159. Bataille F, Klebl F, Rümmele P, Straub RH, Wild P, Schölmerich J, et al. Histopathological parameters as predictors for the course of Crohn's disease. Virchows Arch 2003;443:501–7

160. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749–53.

161. Silverberg MS, Satsangi J, Ahmad T, Arnott ID, Bernstein CN, Brant SR, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005;19(Suppl A): 5–36.

162. Gasche C, Scholmerich J, Brynskov J, D'Haens G, Hanauer SB, Irvine EJ, et al. A simple classification of Crohn's disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis 2000;6: 8–15.

163. Louis E, Collard A, Oger AF, Degroote E, Aboul Nasr El Yafi FA, Belaiche J. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the

disease. Gut 2001;49:777–82.

164. Cosnes J, Cattan S, Blain A, Beaugerie L, Carbonnel F, Parc R, et al. Long-term evolution of disease behavior of Crohn's disease. Inflamm Bowel Dis 2002;8:244–50.

165. Chow DK, Leong RW, Lai LH, Wong GL, Leung WK, Chan FK, et al. Changes in Crohn's disease phenotype over time in the Chinese population: validation of the Montreal classification system. Inflamm Bowel Dis 2008;14:536–41.

166. Markowitz J, Grancher K, Kohn N, Lesser M, Daum F. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000;119:895–902.

167. D'Haens G, Baert F, Van Assche G, Caenepeel P, Vergauwe P, Tuynman H, et al. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet 2008;371: 660–7.

168. Beaugerie L, Seksik P, Nion-Larmurier I, Gendre JP, Cosnes J. Predictors of Crohn's disease. Gastroenterology 2006;130: 650–6.

169. Loly C, Belaiche J, Louis E. Predictors of severe Crohn's disease. Scand J Gastroenterol 2008;43(8):948–54.

170. Seksik P, Loftus Jr EV, Beaugerie L, et al. Validation of predictors of 5-year disabling CD in a population-based cohort from Olmsted County, Minnesota, 1983-1996. Gastroenterology 2007;132:A17.

171. Jones J, Loftus Jr EV, Panaccione R, Chen LS, Peterson S, McConnell J, et al. Relationships between disease activity and serum and fecal biomarkers in patients with Crohn's disease. Clin Gastroenterol Hepatol 2008;6:1218–24.

172. Rutgeerts P, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, et parison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology 2004;126:402–13.

173. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Farkkila M. Crohn's disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn's disease activity index and endoscopic findings. Inflamm Bowel Dis 2008;14: 40–6.

174. Sipponen T, Savilahti E, Karkkainen P, Kolho KL, Nuutinen H, Turunen V, et al. Fecal calprotectin, lactoferrin, and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease. Inflamm Bowel Dis 2008;14(10):1392–8.

175. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008;40: 955–62.

176. Dubinsky MC, Kugathasan S, Mei L, Picornell Y, Nebel J, Wrobel I, et al. Increased immune reactivity predicts aggressive complicating Crohn's disease in children. Clin Gastroenterol Hepatol 2008;6:1105–11.

177. Armuzzi A, Ahmad T, Ling KL, De Silva A, Cullen S, Van Heel, et al. Genotype-phenotype analysis of the Crohn's disease susceptibility haplotype on chromosome 5q31. Gut 2003;52: 1133–9.

The second European evidence-based consensus on the diagnosis and management of Crohn's disease Definitions and diagnosis, European Crohn’s and Colitis Organisation 2009.

1.Colombel JF, Rutgeerts P, Reinisch W, et al. SONIC: a randomized, double blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease naïve to immunomodulators andbiologic therapy. Gut 2008;57 Suppl II:A1.

C, Lichtenstein GR, Krok K, Brensinger CM, Lewis JD. A meta-analysis of the placebo rates of remission and response in clinical trials of active Crohn's disease. Gastroenterology 2004;126:1257–69.

3. Froslie KF, Jahnsen J, Moum BA, VatnMH. Group I. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007;133:412–22.

4. Tung J, Loftus Jr EV, Freese DK, El-Youssef M, Zinsmeister AR, Melton 3rd LJ, et al. A population-based study of the frequency of corticosteroid resistance and dependence in pediatric patients with Crohn's disease and ulcerative colitis. Inflamm Bowel Dis 2006;12:1093–100.

5. Bokemeyer B, Katalinic A, Klugmann T, Franke G, Weismüller J, Ceplis-Kastner S, et al. Predictive factors for a mild course of Crohn's disease. J Crohn's Colitis 2009;3:S82.

6. Seow CH, Benchimol EI, Griffiths AM, Otley AR, Steinhart AH. Budesonide for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2008;3:CD000296.

7. Greenberg GR, Feagan BG, Martin F, et al. Oral budesonide for active Crohn's disease. Canadian Inflammatory Bowel Disease Study Group. New Engl J Med 1994;331:836–41.

8. Rutgeerts P, Lofberg R, Malchow H, et al. A comparison of budesonide with prednisolone for active Crohn's disease. N Engl J Med 1994;331:842–5.

9. Gross V, Andus T, Caesar I, et al. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group. Eur J Gastroenterol Hepatol 1996;8:905–9.

10. Campieri M, Fergusonj A, Doe W, et al. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut 1997;41:209–14.

11. Bar-Meir S, Chowers Y, Lavy A, et al. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. Gastroenterology 1998;115:835–40.

12. Thomsen OO, Cortot A, Jewell DP, et al. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide–Mesalamine Study Group. New Engl J Med 1998;339:370–4.

13. Tromm A, Bunganic I, Tomsova E, et al. Double-blind, doubledummy, randomised, multicentre study to compare the efficacy and safety of oral budesonide (9 mg) and oral mesalazine (4.5 g) in moderately active Crohn's disease patients. Gastroenterology 2009;139(Suppl1):391.